

EU chief says AstraZeneca shortfalls slow vaccine campaign

March 17 2021



AstraZeneca vaccine bottles at a Pharmacy in Edgeware, London, Tuesday, March 16, 2021, as Britain continues use of the vaccine. In recent days, countries including Denmark, Ireland and Thailand have temporarily suspended the use of AstraZeneca's coronavirus vaccine after reports that some people who got a dose developed blood clots, even though there's no evidence that the shot was responsible. The European Medicines Agency and the World Health Organization say the data available do not suggest the vaccine caused the clots.



(AP Photo/Frank Augstein)

The European Union's chief executive criticized Anglo-Swedish vaccinemaker AstraZeneca on Wednesday, accusing the embattled pharmaceutical company of delaying Europe's coronavirus vaccination campaign and warning that the EU is weighing export bans to ensure supplies.

"AstraZeneca has unfortunately under-produced and under-delivered, and this painfully, of course, reduced the speed of the vaccination campaign," European Commission President Ursula von der Leyen told reporters.

Von der Leyen said the company originally pledged to deliver 90 million doses of its shot in the first three months of 2021, but later said it could only provide 40 million, then more recently only 30 million.

Beyond criticism for its slow deliveries, notably in Europe, AstraZeneca also has had to deal with reports of dangerous blood clots in some recipients of its shot, although the company and international regulators say there is no evidence the vaccine is to blame. Several countries, including Germany, France, Italy and Spain, have suspended its use.

The EU's drug regulator insisted Tuesday that there is "no indication" it does so, and von der Leyen said Wednesday that "I trust AstraZeneca, I trust the vaccines."

AstraZeneca's formula is one of three vaccines in use on the continent. But the escalating concern is another setback for the EU's vaccination drive, which has been plagued by shortages and other hurdles and is lagging well behind the campaigns in Britain and the U.S.






European Commission President Ursula von der Leyen speaks during a media conference on the Commissions response to COVID-19 after a meeting of the College of Commissioners at EU headquarters in Brussels, Wednesday, March 17, 2021. The European Commission is proposing Wednesday to create a Digital Green Certificate to facilitate safe free movement inside the EU during the COVID-19 pandemic. (John Thys, Pool via AP)





Pharmacist Rajan Shah prepares a syringe of the AstraZeneca vaccine at St John's Church, in Ealing, London, Tuesday, March 16, 2021. In recent days, countries including Denmark, Ireland and Thailand have temporarily suspended their use of AstraZeneca's coronavirus vaccine after reports that some people who got a dose developed blood clots, even though there's no evidence that the shot was responsible. The European Medicines Agency and the World Health Organization say the data available do not suggest the vaccine caused the clots. Britain and several other countries have stuck with the vaccine. (AP Photo/Kirsty Wigglesworth)





European Commission President Ursula von der Leyen speaks during a media conference on the Commissions response to COVID-19 after a meeting of the College of Commissioners at EU headquarters in Brussels, Wednesday, March 17, 2021. The European Commission is proposing Wednesday to create a Digital Green Certificate to facilitate safe free movement inside the EU during the COVID-19 pandemic. (John Thys, Pool via AP)





European Commission President Ursula von der Leyen gestures after participating in a media conference on the Commissions response to COVID-19 after a meeting of the College of Commissioners at EU headquarters in Brussels, Wednesday, March 17, 2021. The European Commission is proposing Wednesday to create a Digital Green Certificate to facilitate safe free movement inside the EU during the COVID-19 pandemic. (John Thys, Pool via AP)

For the <u>second quarter</u> of 2021, van der Leyen said, AstraZeneca will only deliver 70 million doses, less than half of the 180 million it was "contractually obliged to deliver."

Two production sites in the U.K. figure in the EU's advance purchasing agreement drawn up with AstraZeneca, she said, adding: "We're still waiting for doses to come from the U.K.," she said.



Von der Leyen also noted the EU has exported around 41 million vaccine doses to other countries. "But open roads run in both directions, and this is why we need to ensure that there is reciprocity and proportionality," she said.

"If the situation does not change, we will have to reflect on how to make exports to <u>vaccine</u> producing countries dependent on their level of openness," she added, without naming any country.

She said the EU still aims to vaccinate 70% of all adults by September.

© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: EU chief says AstraZeneca shortfalls slow vaccine campaign (2021, March 17) retrieved 28 April 2024 from https://medicalxpress.com/news/2021-03-eu-chief-astrazeneca-shortfalls-vaccine.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.